Sandoz Narrows 2026 Sales Guidance and Raises Margin Outlook

The company cited temporary challenges in Germany and short-term biosimilar supply constraints. Its SIX-listed shares closed down 2.70% at CHF 79.88 on Oct. 28.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.